FR20C1057I2 - BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS - Google Patents

BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS

Info

Publication number
FR20C1057I2
FR20C1057I2 FR20C1057C FR20C1057C FR20C1057I2 FR 20C1057 I2 FR20C1057 I2 FR 20C1057I2 FR 20C1057 C FR20C1057 C FR 20C1057C FR 20C1057 C FR20C1057 C FR 20C1057C FR 20C1057 I2 FR20C1057 I2 FR 20C1057I2
Authority
FR
France
Prior art keywords
genes
motor neurons
aav vectors
broadcast delivery
peripheral injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1057C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Genethon
Original Assignee
Centre National de la Recherche Scientifique CNRS
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1057(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Genethon filed Critical Centre National de la Recherche Scientifique CNRS
Publication of FR20C1057I1 publication Critical patent/FR20C1057I1/en
Application granted granted Critical
Publication of FR20C1057I2 publication Critical patent/FR20C1057I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
FR20C1057C 2007-10-05 2020-11-17 BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS Active FR20C1057I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301435A EP2058401A1 (en) 2007-10-05 2007-10-05 Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
PCT/EP2008/063297 WO2009043936A1 (en) 2007-10-05 2008-10-03 Widespread gene delivery to motor neurons using peripheral injection of aav vectors
EP08836776.8A EP2212424B2 (en) 2007-10-05 2008-10-03 Widespread gene delivery to motor neurons using peripheral injection of aav vectors

Publications (2)

Publication Number Publication Date
FR20C1057I1 FR20C1057I1 (en) 2020-12-25
FR20C1057I2 true FR20C1057I2 (en) 2024-02-16

Family

ID=39186802

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1057C Active FR20C1057I2 (en) 2007-10-05 2020-11-17 BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS
FR22C1056C Active FR22C1056I1 (en) 2007-10-05 2022-11-17 WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL AAV VECTOR INJECTION

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR22C1056C Active FR22C1056I1 (en) 2007-10-05 2022-11-17 WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL AAV VECTOR INJECTION

Country Status (18)

Country Link
US (3) US9926574B2 (en)
EP (5) EP2058401A1 (en)
JP (2) JP5620819B2 (en)
CN (2) CN101883859A (en)
CA (2) CA2999607A1 (en)
CY (1) CY1125608T1 (en)
DK (2) DK2212424T3 (en)
ES (3) ES2727034T3 (en)
FI (1) FI2212424T4 (en)
FR (2) FR20C1057I2 (en)
HR (2) HRP20220992T3 (en)
HU (2) HUE059864T2 (en)
LT (2) LT3505635T (en)
NO (1) NO2022048I1 (en)
PL (2) PL2212424T3 (en)
PT (3) PT3505635T (en)
SI (2) SI2212424T1 (en)
WO (1) WO2009043936A1 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
WO2013192317A2 (en) * 2012-06-19 2013-12-27 University Of Florida Research Foundation, Inc. Compositions and methods for treating diabetes
EP2019143A1 (en) * 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
PL4160212T3 (en) 2008-01-15 2024-08-12 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
HRP20212024T1 (en) 2009-05-02 2022-04-01 Genzyme Corporation Gene therapy for neurodegenerative disorders
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
WO2011133890A1 (en) * 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
JP5704361B2 (en) * 2010-10-27 2015-04-22 学校法人自治医科大学 Adeno-associated virus virion for gene transfer into nervous system cells
CA2870511C (en) 2011-04-21 2023-08-08 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20130039888A1 (en) * 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
CA2877428A1 (en) * 2012-06-21 2013-12-27 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
AU2013296425B2 (en) 2012-08-01 2018-06-07 Nationwide Children's Hospital, Inc. Intrathecal delivery of recombinant adeno-associated virus 9
EP2895606A4 (en) 2012-09-17 2016-07-06 Res Inst Nationwide Childrens Hospital Compositions and methods for treating amyotrophic lateral sclerosis
EP3622821A1 (en) * 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
HUE050546T2 (en) 2013-08-27 2020-12-28 Res Inst Nationwide Childrens Hospital Products and methods for treatment of amyotrophic lateral sclerosis
WO2015069647A1 (en) 2013-11-05 2015-05-14 The Research Institute At Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
SI3116900T1 (en) * 2014-03-09 2021-02-26 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
EP2933335A1 (en) * 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
WO2016016449A1 (en) 2014-07-31 2016-02-04 Association Institut De Myologie Treatment of amyotrophic lateral sclerosis
EP3200830B1 (en) 2014-10-03 2020-09-09 University of Massachusetts High efficiency library-identified aav vectors
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
RU2020140209A (en) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс RECOMBINANT AAV OPTIONS AND THEIR APPLICATIONS
SG11201703281RA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN107532173A (en) 2014-11-21 2018-01-02 北卡罗来纳-查佩尔山大学 Target the AAV carriers of central nervous system
AU2015364636B9 (en) 2014-12-16 2021-12-02 Board Of Regents Of The University Of Nebraska Gene therapy for Juvenile Batten Disease
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
ES2755725T3 (en) * 2015-04-08 2020-04-23 Us Health Viral gene therapy as treatment for a cholesterol storage disease or disorder
EP3285780A4 (en) 2015-04-24 2018-12-19 University of Massachusetts Modified aav constructions and uses thereof
EP3355938B1 (en) * 2015-10-01 2024-02-07 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
JP6854286B2 (en) * 2015-10-21 2021-04-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Codon-optimized small ATP7A cDNA and use for treating copper transport disorders
CA3002982A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
EP3364996B1 (en) 2015-10-22 2021-08-25 University of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US11826433B2 (en) 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
EP3440210A4 (en) 2016-04-05 2019-11-27 University of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
AU2017250298A1 (en) 2016-04-15 2018-10-11 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
KR102629418B1 (en) 2016-06-13 2024-01-25 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Optimized CLN1 gene and expression cassette and uses thereof
WO2017218852A1 (en) 2016-06-15 2017-12-21 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
JP2019531787A (en) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Biomedical targeting and delivery method and apparatus and system for performing the same
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (en) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 AAV capsid design
CN108524952A (en) * 2017-03-06 2018-09-14 复旦大学 Adeno-associated virus AAV9 and its purposes in the preparation for preparing treatment dagger-axe Xie Shi diseases
CN110913866A (en) 2017-05-05 2020-03-24 沃雅戈治疗公司 Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS)
JP7229989B2 (en) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド Trajectory array guide system
KR20200044793A (en) 2017-08-03 2020-04-29 보이저 테라퓨틱스, 인크. Compositions and methods for delivery of AAV
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (en) 2017-10-16 2024-06-14 沃雅戈治疗公司 Treatment of Amyotrophic Lateral Sclerosis (ALS)
SG11202004406VA (en) * 2017-11-08 2020-06-29 Avexis Inc Means and method for preparing viral vectors and uses of same
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
CN112041437A (en) 2018-02-19 2020-12-04 同源药物公司 Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
BR112020020195A2 (en) 2018-04-03 2021-01-19 Stridebio, Inc. VIRUSES WITH ANTIBODY EVASION
BR112020020266A2 (en) 2018-04-03 2021-01-19 Stridebio, Inc. VIRUSES WITH ANTIBODY EVASION
WO2019200016A1 (en) 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
MX2020012077A (en) 2018-05-15 2021-03-09 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease.
TW202015742A (en) 2018-05-15 2020-05-01 美商航海家醫療公司 Compositions and methods for delivery of aav
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
JP2021529513A (en) 2018-07-02 2021-11-04 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Treatment of amyotrophic lateral sclerosis and spinal cord-related disorders
JP2021530548A (en) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. Systems and methods for producing gene therapy products
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3911410A1 (en) 2019-01-18 2021-11-24 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
KR20210125014A (en) * 2019-02-05 2021-10-15 더 트러스티즈 오브 프린스턴 유니버시티 Recombinant Nucleic Acid Containing Alpha Herpesvirus Promoter Sequence
CN109706176A (en) * 2019-03-12 2019-05-03 青岛大学附属医院 Transfection dorsal root ganglion satellite spongiocyte adenovirus vector construct method can be targeted
AR118465A1 (en) 2019-03-21 2021-10-06 Stridebio Inc RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
MX2021011701A (en) * 2019-03-28 2021-12-10 Massachusetts Gen Hospital Engineered adeno-associated (aav) vectors for transgene expression.
EP3997227A1 (en) * 2019-07-10 2022-05-18 Locanabio, Inc. Rna-targeting knockdown and replacement compositions and methods for use
US20220380413A1 (en) * 2019-08-29 2022-12-01 The Board Of Trustees Of The Leland Stanford Junior University Adeno-Associated Viral Vectors for Crossing the Human Blood Brain Barrier
US20220333133A1 (en) 2019-09-03 2022-10-20 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
CA3157700A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
TW202140791A (en) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 Methods of treating phenylketonuria
IL297200A (en) 2020-04-15 2022-12-01 Voyager Therapeutics Inc Tau binding compounds
PE20230767A1 (en) 2020-05-13 2023-05-09 Voyager Therapeutics Inc TROPISM REDIRECTION OF AAV CAPSIDES
CN112121179A (en) * 2020-09-15 2020-12-25 山东兴瑞生物科技有限公司 Composition and application thereof in treating spinal muscular atrophy
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115708866A (en) * 2021-08-23 2023-02-24 中国科学院深圳先进技术研究院 Application of bone origin factor RANKL in preparation of medicine or medicine composition for regulating and controlling central nervous system homeostasis
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3235632A1 (en) 2021-11-02 2023-05-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
TW202334181A (en) 2021-11-17 2023-09-01 美商航海家醫療公司 Aav capsid variants and uses thereof
TW202346599A (en) 2022-02-08 2023-12-01 美商航海家醫療公司 Aav capsid variants and uses thereof
TW202417466A (en) 2022-06-02 2024-05-01 美商航海家醫療公司 Aav capsid variants and uses thereof
TW202417467A (en) 2022-06-28 2024-05-01 美商航海家醫療公司 Aav capsid variants and uses thereof
WO2024011112A1 (en) 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
CN116064671A (en) * 2022-08-10 2023-05-05 深圳先进技术研究院 Application of gene delivery system in delivering genes to microglia
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024145474A2 (en) 2022-12-29 2024-07-04 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222574A1 (en) 1995-06-07 1996-12-19 Yale University Oral delivery of adeno-associated viral vectors
US20040076613A1 (en) 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
FR2756297B1 (en) 1996-11-22 1999-01-08 Centre Nat Rech Scient PROCESS FOR PRODUCING RECOMBINANT VIRUSES
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
US6399385B1 (en) 1999-09-29 2002-06-04 The Trustees Of The University Of Pennsylvania Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
AU1775901A (en) 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
CA2410828C (en) 2000-06-01 2012-01-24 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
EP1286703B1 (en) 2000-06-01 2009-08-05 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
US20050032219A1 (en) 2001-07-03 2005-02-10 Patrick Aubourg Methods of administering vectors to synaptically connected neurons
CN102181480B (en) * 2001-11-13 2016-01-27 宾夕法尼亚大学托管会 Detect and/or identify the method for the novel sequences that adeno associated virus (AAV) sequence and separation are identified
PT2573170T (en) 2001-12-17 2018-03-26 Univ Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
CA2469658A1 (en) 2001-12-19 2003-07-03 Lijun Wang Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
IL162630A0 (en) * 2001-12-21 2005-11-20 Salk Inst For Biological Studi A composition containing a viral vector containinga heterologous gene to be transduced into a neuron
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
EP1608763A2 (en) * 2003-03-31 2005-12-28 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
WO2004106517A1 (en) * 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded nucleic acid
DK2357189T3 (en) 2003-06-19 2017-06-19 Genzyme Corp AAV virions with reduced immunoreactivity and applications thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2005033321A2 (en) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2005037211A2 (en) * 2003-10-14 2005-04-28 Neurologix Research, Inc. Methods and compositions for the treatment of neurological disease
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8137960B2 (en) 2003-12-04 2012-03-20 The United States Of America As Represented By The Department Of Health And Human Services Bovine adeno-associated viral (BAAV) vector and uses thereof
WO2005072364A2 (en) 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
EP1732383A4 (en) * 2004-04-06 2007-05-02 Cedars Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
JP2008503590A (en) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド Medical systems and methods for delivering compositions to cells
US20060110364A1 (en) * 2004-08-20 2006-05-25 Ludwig Institute For Cancer Research Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
ES2394482T3 (en) 2005-05-02 2013-02-01 Genzyme Corporation Gene therapy for spinal cord disorders
WO2007089632A2 (en) * 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US20070280906A1 (en) 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
US20100221225A1 (en) * 2007-02-23 2010-09-02 University Of Florida Research Foundation, Inc Compositions and methods for treating glycogen storage diseases
WO2008150459A1 (en) 2007-05-30 2008-12-11 The Trustees Of The University Of Pennsylvania A method for transducing cells with primary cilia
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
BRPI0817937A2 (en) 2007-10-01 2015-04-07 Alcon Res Ltd Self-complementing αv-mediated delivery of interfering rna molecules to treat or prevent eye disorders
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9

Also Published As

Publication number Publication date
CA2999607A1 (en) 2009-04-09
CY1125608T1 (en) 2023-06-09
PL3505635T3 (en) 2022-09-12
HUS2200047I1 (en) 2022-12-28
CA2701561A1 (en) 2009-04-09
LT3505635T (en) 2022-09-12
US9926574B2 (en) 2018-03-27
CN101883859A (en) 2010-11-10
US11767538B2 (en) 2023-09-26
US20100240739A1 (en) 2010-09-23
HRP20220992T3 (en) 2022-11-11
PT3505635T (en) 2022-08-12
NO2022048I1 (en) 2022-11-16
FR22C1056I1 (en) 2023-01-06
EP2212424B1 (en) 2014-06-11
WO2009043936A1 (en) 2009-04-09
EP3505635A1 (en) 2019-07-03
ES2482094T3 (en) 2014-08-01
US20180066283A1 (en) 2018-03-08
EP2212424B2 (en) 2023-11-01
ES2482094T5 (en) 2024-06-03
JP6309373B2 (en) 2018-04-11
US20200010852A1 (en) 2020-01-09
PL2212424T3 (en) 2014-11-28
FR20C1057I1 (en) 2020-12-25
CN105087650A (en) 2015-11-25
ES2727034T3 (en) 2019-10-11
EP3505635B1 (en) 2022-05-18
EP2058401A1 (en) 2009-05-13
SI2212424T1 (en) 2014-12-31
EP2212424A1 (en) 2010-08-04
CA2701561C (en) 2018-05-15
EP2527457B1 (en) 2019-02-20
PT2212424E (en) 2014-07-25
DK2212424T3 (en) 2014-07-14
DK3505635T3 (en) 2022-08-22
JP2014221789A (en) 2014-11-27
SI3505635T1 (en) 2022-10-28
HUE059864T2 (en) 2023-01-28
HRP20140643T1 (en) 2014-11-07
LTPA2022525I1 (en) 2022-12-12
PT2527457T (en) 2019-05-31
EP3854878A1 (en) 2021-07-28
FI2212424T4 (en) 2023-12-15
EP2527457A1 (en) 2012-11-28
ES2924892T3 (en) 2022-10-11
JP5620819B2 (en) 2014-11-05
JP2010540598A (en) 2010-12-24

Similar Documents

Publication Publication Date Title
FR20C1057I2 (en) BROADCAST DELIVERY OF GENES TO MOTOR NEURONS BY PERIPHERAL INJECTION OF AAV VECTORS
FR20C1058I1 (en) GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM BY PERIPHERAL DELIVERY OF AAV VECTOR
CL2007003879A1 (en) COMPOUNDS DERIVED FROM ARIL-CARBOXAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS ALZHEIMER, EPILEPSY AND PARKINSON.
BRPI0814624A2 (en) TREATMENT OF PROGRESIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
DE602007003834D1 (en) STEERING SYSTEM MOTOR
CL2009000990A1 (en) Use of epothilone d for the treatment of diseases associated with tau, such as Alzheimer's disease, Parkinson's, among others.
IL210813A0 (en) Methods of administering topical antifungal formulations for the treatment of fungal infections
EP2334176A4 (en) Topical formulations for treatment of neuropathy
BRPI0917497A2 (en) plasma renin mass spectrometry assay
DE602008005545D1 (en) Fuel injection control device
FI20070063A0 (en) Organic field effect transistor
DE602008005797D1 (en) engine
EP2342444A4 (en) Insensitive rocket motor
DE102008033675B8 (en) Dual core engine control module architecture
FR2934817B1 (en) VEHICLE OF SMALL SIZE.
BRPI0909653A2 (en) stabilized transdermal therapeutic system
BRPI0915422A2 (en) improved cholesterol efflux peptide mediators
EP2252881A4 (en) Complete structure elucidation of molecules utilizing single nmr experiment
IT1391506B1 (en) MOTOR AXIS
DE502008000044D1 (en) Fuel distributor
FI20060861A0 (en) Arrangements to protect an electric motor
SE0850158L (en) Fuel injection device for engine
BRPI0909364A2 (en) multi fuel engine fuel injection control device
PL2304212T3 (en) Solid-propellant rocket motor
BRPI0716766A2 (en) Amino Alcohol Nitrate Esters